Fosun Pharma advances with ketoprofen patch and Serplulimab approval

Shanghai Fosun Pharmaceutical Group's subsidiary, Shanghai Zhaohui Pharmaceutical Co., Ltd., has received approval from China's National Medical Products Administration to conduct phase III clinical trials for its ketoprofen patch. This chemical drug, for various pain and inflammation conditions, represents a cumulative R&D investment of approximately CNY 960,000 as of October 2025.

Concurrently, another subsidiary, Shanghai Henlius Biotech, has had its application accepted for Serplulimab Injection (Hansizhuang®) for an expanded indication in gastric cancer, which has been granted priority review.

Serplulimab, an innovative anti-PD-1 monoclonal antibody, has already been approved in China, the EU, UK, and other regions for multiple indications, including lung and esophageal cancers. Cumulative R&D investment for Serplulimab (monotherapy and various combination therapies) by the group reached approximately CNY 3.495 billion as of October 2025. This dual progress highlights Fosun Pharma's ongoing commitment to pharmaceutical innovation and market expansion.